8-K: Tonix Pharmaceuticals Announces FDA Clearance for TNX-102 SL Trial in Acute Stress Reduction

Tonix Pharmaceuticals has received FDA clearance for an investigator-initiated trial of TNX-102 SL to evaluate its effectiveness in reducing acute stress reaction and preventing stress disorders.

Summary

• Tonix Pharmaceuticals announced that the FDA has cleared the Investigational New Drug (IND) application for the OASIS trial.
• The OASIS trial will evaluate TNX-102 SL in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).
• The trial is funded by a $3 million grant from the U.S. Department of Defense (DoD) and sponsored by The University of North Carolina (UNC) Institute for Trauma Recovery.
• The Phase 2 trial will enroll approximately 180 trauma survivors at emergency department study sites across the U.S.
• Participants will be randomized to receive either TNX-102 SL 5.6 mg or a placebo for two weeks.
• The company also updated its investor presentation, which includes nonpublic information and will be placed on their website.
• Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA clearance for the OASIS trial, the progress of Tonmya towards NDA submission, and the funding received from the DoD. The company is making significant progress in its clinical programs and has a clear path forward. However, the inherent risks in pharmaceutical development and the forward-looking nature of the statements temper the overall sentiment.

Positives

• FDA clearance of the IND application for the OASIS trial is a positive step for the development of TNX-102 SL.
• The $3 million grant from the DoD provides significant funding for the trial.
• The investigator-initiated trial at UNC leverages existing infrastructure and expertise.
• The company has completed two positive Phase 3 studies for Tonmya for fibromyalgia.
• The company is on track to submit an NDA for Tonmya in the second half of 2024.
• The updated investor presentation provides transparency and information to stakeholders.

Negatives

• The press release and investor presentation contain forward-looking statements that are subject to risks and uncertainties.
• The company's product candidates are still investigational and have not been approved for any indication.
• The company is dependent on third parties for research and development efforts.
• There is substantial competition in the pharmaceutical industry.

Risks

• The company faces risks related to obtaining FDA clearances or approvals.
• There are risks related to the successful marketing of any of their products.
• The timing and progress of clinical development of product candidates are uncertain.
• The company may need additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third-party payor reimbursement.
• The company faces substantial competition in the pharmaceutical industry.

Future Outlook

Tonix plans to submit an NDA for Tonmya for fibromyalgia in the second half of 2024 and expects an FDA decision in the second half of 2025. They also plan to initiate Phase 2 studies for TNX-102 SL in acute stress disorder and TNX-1300 for cocaine intoxication in the first quarter of 2024. The company is also advancing other pipeline programs and exploring strategic partnerships.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix, stated that there is an unmet need for treating ASR after traumatic events.
• Samuel McLean, M.D., Professor of Psychiatry and Emergency Medicine at the UNC School of Medicine, said that the clinical trial will help address the need for safe and effective therapies to treat acute trauma.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the areas of central nervous system disorders, pain management, and trauma treatment. The development of TNX-102 SL for acute stress reaction and PTSD addresses a significant unmet need in both civilian and military populations. The company's focus on non-opioid analgesics aligns with the industry's efforts to find alternatives to opioids for pain management.

Comparison to Industry Standards

• The development of TNX-102 SL for fibromyalgia is in line with the industry's focus on addressing chronic pain conditions, with competitors such as Lyrica, Cymbalta, and Savella already on the market, though with limitations.
• The OASIS trial for acute stress reaction is unique as there are currently no medications available at or near the point-of-care to treat patients suffering from traumatic events.
• Tonix's approach to developing a sublingual formulation of cyclobenzaprine is differentiated from standard oral formulations, potentially offering better tolerability and efficacy.
• The company's focus on a non-opioid analgesic for fibromyalgia addresses a significant unmet need, as many patients do not respond to or cannot tolerate existing therapies.
• The development of TNX-1300 as a fast-acting antidote for cocaine intoxication is a novel approach, as there are currently no other products on the market for this indication.
• The company's work on TNX-1500, a next-generation anti-CD40L monoclonal antibody, is aimed at improving safety and efficacy compared to first-generation antibodies that were halted due to thromboembolic complications.

Stakeholder Impact

• Shareholders will likely view the FDA clearance and progress of clinical trials positively.
• Employees may be motivated by the company's advancements and potential for growth.
• Patients with fibromyalgia, acute stress reaction, and other conditions may benefit from the development of new therapies.
• The company's partnerships with government and academic institutions may enhance its credibility and access to resources.

Next Steps

• Initiate Phase 2 study of TNX-102 SL for acute stress disorder in the first quarter of 2024.
• Initiate Phase 2 study of TNX-1300 for the treatment of cocaine intoxication in the first quarter of 2024.
• Conduct a pre-NDA meeting with the FDA for Tonmya for fibromyalgia in the first half of 2024.
• Report results of Phase 1 study of TNX-1500 in the third quarter of 2024.
• Submit an NDA to the FDA for Tonmya for fibromyalgia in the second half of 2024.

Key Dates

Keywords

TNX-102 SL, OASIS trial, acute stress reaction, acute stress disorder, PTSD, fibromyalgia, Tonmya, FDA, clinical trial, investigational new drug, Department of Defense, UNC, investor presentation